Advanced search
Publication Cover
Acta Oncologica Volume 59, 2020 - Issue 12
Journal homepage
1,420
Views
2
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: MEDICAL ONCOLOGY AND HEMATHOLOGY

Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma

Michael Asger Andersena Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;b Department of Epidemiology Research, Statens Serum Institut, Copenhagen, DenmarkCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9729-9974View further author information
ORCID Icon,
Rebecca Valentina Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-8339-0902View further author information
ORCID Icon,
Lene Dissing Sjöd Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkView further author information
,
Line Borgwardte Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkView further author information
,
Kjeld Schmiegelowf Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark;g Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, DenmarkORCID Iconhttps://orcid.org/0000-0002-0829-4993View further author information
ORCID Icon,
Mette Klarskov Andersend Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;h Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkView further author information
,
Rasmus L. Marvige Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkView further author information
,
Christina Westmose Ydee Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkView further author information
&
Carsten Utoft Niemanna Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkORCID Iconhttps://orcid.org/0000-0001-9880-5242View further author information
ORCID Icon show all
Pages 1547-1551 | Received 12 Jun 2020, Accepted 07 Sep 2020, Published online: 24 Sep 2020

References

  • Herling M, Khoury JD, Washington LBT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104(2):328–335.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Taylor A, Metcalfe J, Thick J, et al. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87(2):423–438.
  • Andersson EI, Pützer S, Yadav B, et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018;32(3):774–787.
  • Boidol B, Kornauth C, Van Der Kouwe E, et al. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017;130(23):2499–2503.
  • He L, Tang J, Andersson EI, et al. Patient-customized drug combination prediction and testing for t-cell prolymphocytic leukemia patients. Cancer Res. 2018;78(9):2407–2418.
  • Hasanali ZS, Saroya BS, Stuart A, et al. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Sci Transl Med. 2015;7(293):293ra102–293ra102. ra
  • Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134(14):1132–1143.
  • Soderquist CR, Bhagat G. Gastrointestinal T- and NK-cell lymphomas and indolent lymphoproliferative disorders. Semin Diagn Pathol. 2020;37(1):11–23.
  • Schoenaker MHD, Henriet SS, Zonderland J, et al. Immunodeficiency in Bloom's syndrome. J Clin Immunol. 2018;38(1):35–44.
  • German J, Sanz MM, Ciocci S, et al. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat. 2007;28(8):743–753.
  • Sud A, Thomsen H, Sundquist K, et al. Risk of second cancer in Hodgkin lymphoma survivors and influence of family history. J Cin Oncol. 2017;35(14):1584–1590.
  • Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Progr. 2008;2008(1):450–456.
  • Springuel L, Renauld JC, Knoops L. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica. 2015;100(10):1240–1253.
  • Li G, Waite E, Wolfson J. T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). Blood Adv. 2017;1(27):2724–2728.
  • Fukuyama T, Tschernig T, Qi Y, et al. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. Eur J Pharmacol. 2015;764:278–282.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.